Complete title: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Sarcoma, Colon, Non-Hodgkin Lymphoma, Non-Small Cell Lung, Squamous Cell Head and Neck Cancer and Cutaneous Squamous Cell Cancer
|Research Study Number||9103A|
|Principal Investigator||Sylvia Lee, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Melanoma; Solid Tumors; Neuroendocrine Tumor; Immunotherapy
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.